Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
Public ClinicalTrials.gov record NCT03872206. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy
Study identification
- NCT ID
- NCT03872206
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 95 participants
Conditions and interventions
Interventions
- 2 Prime Step IV 900-14000 ng/kg Target Biological
- HPN536 1 Prime Step IV 600-1200 ng/kg Target Biological
- HPN536 Fixed IV 6 to 560 ng/kg Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2019
- Primary completion
- Jan 3, 2023
- Completion
- Jan 3, 2023
- Last update posted
- Jun 6, 2024
2019 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| University of Southern California | Los Angeles | California | 90007 | — |
| University of California Los Angeles | Los Angeles | California | 90095-7170 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10017 | — |
| Cleveland Clinic Taussig Cancer Institute | Cleveland | Ohio | 44195 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22903 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03872206, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03872206 live on ClinicalTrials.gov.